Genetic variability of pain perception and treatment - Clinical pharmacological implications

European Journal of Clinical Pharmacology

Volumn 67, Issue 6, 2011, Pages 541-551

  Lötsch, Jörn ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Analgesics; Drug targets; Investigational drugs; Pain genetics; Personalized medicine; Pharmacogenetics

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; CODEINE; DIAMORPHINE; GUANOSINE TRIPHOSPHATE CYCLOHYDROLASE I; MERCAPTOPURINE; METHADONE; MORPHINE; NARCOTIC ANALGESIC AGENT; NERVE GROWTH FACTOR; POTASSIUM CHANNEL KV9.1; SODIUM CHANNEL NAV1.7; TRAMADOL; TRANSIENT RECEPTOR POTENTIAL CHANNEL A1; UNCLASSIFIED DRUG; VOLTAGE GATED POTASSIUM CHANNEL;

ANALGESIA; CANCER PAIN; DISEASE CONTROL; DIZZINESS; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG TARGETING; DRUG TRANSPORT; EUPHORIA; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE; HEROIN DEPENDENCE; HUMAN; NEUROPATHY; NOCICEPTION; NONHUMAN; OPIATE ADDICTION; PAIN; PHARMACODYNAMICS; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT;

ANALGESICS; DNA FINGERPRINTING; GENOTYPE; HUMANS; MOLECULAR TARGETED THERAPY; PAIN; PAIN PERCEPTION; PHENOTYPE;

EID: 79959719115     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-011-1012-9     Document Type: Review

References (114)

1. Godinova AM (1967) Phenotypic manifestations and genetic features of migraine. Zh Nevropatol Psikhiatr Im S S Korsakova 67(7):1002-1007
2. Lötsch J, Geisslinger G (2010) A critical appraisal of human genotyping for pain therapy. Trends Pharmacol Sci 31:312-317
3. Lötsch J, Geisslinger G, Tegeder I (2009) Genetic modulation of the pharmacological treatment of pain. Pharmacol Ther 124 (2):168-184
4. Lötsch J, Skarke C, Liefhold J, Geisslinger G (2004) Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives. Clin Pharmacokinet 43(14):983-1013 (Pubitemid 39602014)
5. Oertel B, Lötsch J (2008) Genetic mutations that prevent pain: implications for future pain medication. Pharmacogenomics 9(2):179-194 (Pubitemid 351566942)
6. Fiore M, Chaldakov GN, Aloe L (2009) Nerve growth factor as a signaling molecule for nerve cells and also for the neuroendocrine-immune systems. Rev Neurosci 20:133-145
7. Hefti FF, Rosenthal A, Walicke PA, Wyatt S, Vergara G, Shelton DL, Davies AM (2006) Novel class of pain drugs based on antagonism of NGF. Trends Pharmacol Sci 27:85-91 (Pubitemid 43184029)
8. Einarsdottir E, Carlsson A, Minde J, Toolanen G, Svensson O, Solders G, Holmgren G, Holmberg D, Holmberg M (2004) A mutation in the nerve growth factor beta gene (NGFB) causes loss of pain perception. Hum Mol Genet 13(8):799-805 (Pubitemid 38515209)
9. Lane NE, Schnitzer TJ, Birbara CA, Mokhtarani M, Shelton DL, SmithMD, BrownMT (2010) Tanezumab for the treatment of pain from osteoarthritis of the knee. N Engl J Med 363(16):1521-1531
10. Schnitzer TJ, Lane NE, Birbara C, Smith MD, Simpson SL, Brown MT (2011) Long-term open- label study of tanezumab for moderate to severe osteoarthritic knee pain. Osteoarthritis Cartilage. doi:10.1016/j.joca.2011.01.009
11. Smeyne RJ, Klein R, Schnapp A, Long LK, Bryant S, Lewin A, Lira SA, Barbacid M (1994) Severe sensory and sympathetic neuropathies in mice carrying a disrupted Trk/NGF receptor gene. Nature 368(6468):246-249 (Pubitemid 24108841)
12. Indo Y, Tsuruta M, Hayashida Y, Karim MA, Ohta K, Kawano T, Mitsubuchi H, Tonoki H, Awaya Y, Matsuda I (1996) Mutations in the TRKA/NGF receptor gene in patients with congenital insensitivity to pain with anhidrosis. Nat Genet 13(4):485-488 (Pubitemid 26256627)
13. Indo Y (2001) Molecular basis of congenital insensitivity to pain with anhidrosis (CIPA): mutations and polymorphisms in TRKA (NTRK1) gene encoding the receptor tyrosine kinase for nerve growth factor. Hum Mutat 18(6):462-471
14. Mantegazza M, Curia G, Biagini G, Ragsdale DS, Avoli M (2010) Voltage-gated sodium channels as therapeutic targets in epilepsy and other neurological disorders. Lancet Neurol 9:413-424
15. Cox JJ, Reimann F, Nicholas AK, Thornton G, Roberts E, Springell K, Karbani G, Jafri H, Mannan J, Raashid Y, Al-Gazali L, Hamamy H, Valente EM, Gorman S, Williams R, McHale DP, Wood JN, Gribble FM, Woods CG (2006) An SCN9A channelopathy causes congenital inability to experience pain. Nature 444(7121):894-898 (Pubitemid 46024997)
16. Nilsen KB, Nicholas AK,Woods CG, Mellgren SI, Nebuchennykh M, Aasly J (2009) Two novel SCN9A mutations causing insensitivity to pain. Pain 143(1-2):155-158
17. Staud R, Price DD, Janicke D, Andrade E, Hadjipanayis AG, Eaton WT, Kaplan L, Wallace MR (2010) Two novel mutations of SCN9A (Nav1.7) are associated with partial congenital insensitivity to pain. Eur J Pain. doi:10.1016/j. ejpain.2010.07.003
18. Lariviere WR, Mogil JS (2010) The genetics of pain and analgesia in laboratory animals. Methods Mol Biol 617:261-278
19. Tegeder I, Costigan M, Griffin RS, Abele A, Belfer I, Schmidt H, Ehnert C, Nejim J, Marian C, Scholz J, Wu T, Allchorne A, Diatchenko L, Binshtok AM, Goldman D, Adolph J, Sama S, Atlas SJ, Carlezon WA, Parsegian A, Lötsch J, Fillingim RB, Maixner W, Geisslinger G, Max MB, Woolf CJ (2006) GTP cyclohydrolase and tetrahydrobiopterin regulate pain sensitivity and persistence. Nat Med 12(11):1269-1277 (Pubitemid 44706929)
20. Auerbach G, Nar H (1997) The pathway from GTP to tetrahydrobiopterin: three-dimensional structures of GTP cyclohydrolase I and 6-pyruvoyl tetrahydropterin synthase. Biol Chem 378(3-4):185-192 (Pubitemid 27230601)
21. Thony B, Auerbach G, Blau N (2000) Tetrahydrobiopterin biosynthesis, regeneration and functions. Biochem J 347(Pt 1):1-16
22. Tegeder I, Adolph J, Schmidt H, Woolf CJ, Geisslinger G, Lötsch J (2008) Reduced hyperalgesia in homozygous carriers of a GTP cyclohydrolase 1 haplotype. Eur J Pain 12(8):1069-1077
23. Campbell CM, Edwards RR, Carmona C, Uhart M, Wand G, Carteret A, Kim YK, Frost J, Campbell JN (2009) Polymorphisms in the GTP cyclohydrolase gene (GCH1) are associated with ratings of capsaicin pain. Pain 141(1-2):114-118
24. Doehring A, Freynhagen R, Griessinger N, Zimmermann M, Sittl R, Hentig N, Geisslinger G, Lötsch J (2009) Cross-sectional assessment of the consequences of a GTP cyclohydrolase 1 haplotype for specialized tertiary outpatient pain care. Clin J Pain 25(9):781-785
25. Lötsch J, Klepstad P, Doehring A, Dale O (2010) A GTP cyclohydrolase 1 genetic variant delays cancer pain. Pain 148:103-106
26. Kim H, Dionne RA (2007) Lack of influence of GTP cyclohydrolase gene (GCH1) variations on pain sensitivity in humans. Mol Pain 3:6
27. Lazarev M, Lamb J, Barmada Pitt Edu MM, Dai F, Anderson MA, Max MB, Whitcomb DC (2008) Does the pain-protective GTP cyclohydrolase haplotype significantly alter the pattern or severity of pain in humans with chronic pancreatitis? Mol Pain 4(1):58
28. Zhang L, Rao F, Zhang K, Khandrika S, Das M, Vaingankar SM, Bao X, Rana BK, Smith DW, Wessel J, Salem RM, Rodriguez-Flores JL, Mahata SK, Schork NJ, Ziegler MG, O'Connor DT (2007) Discovery of common human genetic variants of GTP cyclohydrolase 1 (GCH1) governing nitric oxide, autonomic activity, and cardiovascular risk. J Clin Invest 117(9):2658-2671 (Pubitemid 47494366)
29. Doehring A, Antoniades C, Channon KM, Tegeder I, Lötsch J (2008) Clinical genetics of functionally mild non-coding GTP cyclohydrolase 1 (GCH1) polymorphisms modulating pain and cardiovascular risk. Mutat Res 659(3):195-201
30. Costigan M, Belfer I, Griffin RS, Dai F, Barrett LB, Coppola G, Wu T, Kiselycznyk C, Poddar M, Lu Y, Diatchenko L, Smith S, Cobos EJ, Zaykin D, Allchorne A, Shen PH, Nikolajsen L, Karppinen J, Mannikko M, Kelempisioti A, Goldman D, Maixner W, Geschwind DH, Max MB, Seltzer Z, Woolf CJ (2010) Multiple chronic pain states are associated with a common amino acid-changing allele in KCNS1. Brain 133(9):2519-2527
31. Maitland ML, Vasisht K, Ratain MJ (2006) TPMT, UGT1A1 and DPYD: genotyping to ensure safer cancer therapy? Trends Pharmacol Sci 27(8):432-437
32. Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M, Karrison T, Janisch L, Ramirez J, Rudin CM, Vokes EE, Ratain MJ (2004) Genetic variants in the UDP- glucuronosyl-transferase1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 22(8):1382-1388 (Pubitemid 41103619)
33. Relling MV, Hancock ML, Rivera GK, Sandlund JT, Ribeiro RC, Krynetski EY, Pui CH, Evans WE (1999) Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst 91(23):2001-2008
34. Kim H, Dionne RA (2005) Genetics, pain, and analgesia (volume XIII, no. 3). http://www.iasp-pain.org/AM/TemplateRedirect.cfm?template=/CM/ ContentDisplay.cfm&ContentID=7637
35. Kim H, Clark D, Dionne RA (2009) Genetic contributions to clinical pain and analgesia: avoiding pitfalls in genetic research. J Pain 10(7):663-693
36. Lötsch J, Geisslinger G (2006) Current evidence for a genetic modulation of the response to analgesics. Pain 121(1-2):1-5 (Pubitemid 43261625)
37. Lötsch J, Geisslinger G (2005) Are mu-opioid receptor polymorphisms important for clinical opioid therapy? Trends Mol Med 11(2):82-89
38. Nishizawa D, Nagashima M, Katoh R, Satoh Y, Tagami M, Kasai S, Ogai Y, Han W, Hasegawa J, Shimoyama N, Sora I, Hayashida M, Ikeda K (2009) Association between KCNJ6 (GIRK2) gene polymorphisms and postoperative analgesic requirements after major abdominal surgery. PLoS ONE 4(9):e7060
39. Lee YS, Kim H, Wu TX, Wang XM, Dionne RA (2006) Genetically mediated interindividual variation in analgesic responses to cyclooxygenase inhibitory drugs. Clin Pharmacol Ther 79(5):407-418
40. Oertel BG, Kettner M, Scholich K, Renne C, Roskam B, Geisslinger G, Schmidt PH, Lötsch J (2009) A Common Human mu-Opioid Receptor Genetic Variant Diminishes the Receptor Signaling Efficacy in Brain Regions Processing the Sensory Information of Pain. J Biol Chem 284(10):6530-6535
41. Zhang Y, Wang D, Johnson AD, Papp AC, Sadee W (2005) Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G. J Biol Chem 280 (38):32618-32624 (Pubitemid 41368304)
42. Bond C, LaForge KS, Tian M, Melia D, Zhang S, Borg L, Gong J, Schluger J, Strong JA, Leal SM, Tischfield JA, Kreek MJ, Yu L (1998) Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci USA 95(16):9608-9613 (Pubitemid 28506279)
43. Lötsch J, Zimmermann M, Darimont J, Marx C, Dudziak R, Skarke C, Geisslinger G (2002) Does the A118G polymorphism at the mu-opioid receptor gene protect against morphine-6-glucuronide toxicity? Anesthesiology 97(4):814-819
44. Walter C, Lötsch J (2009) Meta-analysis of the relevance of the OPRM1 118A>G genetic variant for pain treatment. Pain 146(3):270-275
45. Hirota T, Ieiri I, Takane H, Sano H, Kawamoto K, Aono H, Yamasaki A, Takeuchi H, Masada M, Shimizu E, Higuchi S, Otsubo K (2003) Sequence variability and candidate gene analysis in two cancer patients with complex clinical outcomes during morphine therapy. Drug Metab Dispos 31(5):677-680 (Pubitemid 36444178)
46. Oertel BG, Schmidt R, Schneider A, Geisslinger G, Lötsch J (2006) The mu-opioid receptor gene polymorphism 118A>G depletes alfentanil-induced analgesia and protects against respiratory depression in homozygous carriers. Pharmacogenet Genomics 16(9):625-636 (Pubitemid 44223074)
47. Shabalina SA, Zaykin DV, Gris P, Ogurtsov AY, Gauthier J, Shibata K, Tchivileva IE, Belfer I, Mishra B, Kiselycznyk C, Wallace MR, Staud R, Spiridonov NA, Max MB, Goldman D, Fillingim RB, Maixner W, Diatchenko L (2009) Expansion of the Human mu-Opioid Receptor Gene Architecture: Novel Functional Variants. Hum Mol Genet 18:1037-1051
48. Gris P, Gauthier J, Cheng P, Gibson DG, Gris D, Laur O, Pierson J, Wentworth S, Nackley AG, Maixner W, Diatchenko L (2010) A novel alternatively spliced isoform of the mu-opioid receptor: functional antagonism. Mol Pain 6:33
49. Berthele A, Platzer S, Jochim B, Boecker H, Buettner A, Conrad B, Riemenschneider M, Toelle TR (2005) COMT Val108/158Met genotype affects the mu-opioid receptor system in the human brain: evidence from ligand-binding, G-protein activation and preproenkephalin mRNA expression. Neuroimage 28(1):185-193
50. Zubieta JK, Heitzeg MM, Smith YR, Bueller JA, Xu K, Xu Y, Koeppe RA, Stohler CS, Goldman D (2003) COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor. Science 299(5610):1240-1243 (Pubitemid 36237467)
51. Rakvag TT, Klepstad P, Baar C, Kvam TM, Dale O, Kaasa S, Krokan HE, Skorpen F (2005) The Val158Met polymorphism of the human catechol-O- methyltransferase (COMT) gene may influence morphine requirements in cancer pain patients. Pain 116(1-2):73-78 (Pubitemid 40828502)
52. Lacroix-Fralish ML, Ledoux JB, Mogil JS (2007) The Pain Genes Database: An interactive web browser of pain-related transgenic knockout studies. Pain 131(1-2):3e1-3e4
53. Mitrovic I, Margeta-Mitrovic M, Bader S, Stoffel M, Jan LY, Basbaum AI (2003) Contribution of GIRK2-mediated postsynaptic signaling to opiate and alpha 2-adrenergic analgesia and analgesic sex differences. Proc Natl Acad Sci USA 100(1):271-276 (Pubitemid 36078064)
54. Kobayashi T, Ikeda K, Kojima H, Niki H, Yano R, Yoshioka T, Kumanishi T (1999) Ethanol opens G-protein-activated inwardly rectifying K+ channels. Nat Neurosci 2:1091-1097 (Pubitemid 30126367)
55. Marker CL, Stoffel M, Wickman K (2004) Spinal G-proteingated K+ channels formed by GIRK1 and GIRK2 subunits modulate thermal nociception and contribute to morphine analgesia. J Neurosci 24(11):2806-2812 (Pubitemid 38380958)
56. Lötsch J, Prüss H, Veh RW, Doehring A (2010) A KCNJ6 (Kir3.2, GIRK2) gene polymorphism modulates opioid effects on analgesia and addiction but not on pupil size. Pharmacogenet Genomics 20(5):291-297
57. Mogil JS, Wilson SG, Chesler EJ, Rankin AL, Nemmani KV, Lariviere WR, Groce MK, Wallace MR, Kaplan L, Staud R, Ness TJ, Glover TL, Stankova M, Mayorov A, Hruby VJ, Grisel JE, Fillingim RB (2003) The melanocortin-1 receptor gene mediates female-specific mechanisms of analgesia in mice and humans. Proc Natl Acad Sci USA 100(8):4867-4872 (Pubitemid 36457820)
58. Skarke C, Reus M, Schmidt R, Grundei I, Schuss P, Geisslinger G, Lötsch J (2006) The cyclooxygenase 2 genetic variant -765G>C does not modulate the effects of celecoxib on prostaglandin E2 production. Clin Pharmacol Ther 80(6):621-632 (Pubitemid 44908271)
59. Rodger IW (2009) Analgesic targets: today and tomorrow. Inflammopharmacology 17:151-161
60. Clare JJ (2010) Targeting voltage-gated sodium channels for pain therapy. Expert Opin Investig Drugs 19:45-62
61. Patapoutian A, Tate S, Woolf CJ (2009) Transient receptor potential channels: targeting pain at the source. Nat Rev Drug Discov 8(1):55-68
62. Choi J-S, Cheng X, Foster E, Leffler A, Tyrrell L, Te Morsche RHM, Eastman EM, Jansen HJ, Huehne K, Nau C, Dib-Hajj SD, Drenth JPH, Waxman SG (2010) Alternative splicing may contribute to time-dependent manifestation of inherited erythromelalgia. Brain 133:1823-1835
63. Norbury TA, MacGregor AJ, Urwin J, Spector TD, McMahon SB (2007) Heritability of responses to painful stimuli in women: a classical twin study. Brain 130(Pt 11):3041-3049 (Pubitemid 350033971)
64. Ahn H-S, Dib-Hajj S, Cox JJ, Tyrell L, Elmslie FV, Clarke AA, Drenth JPH, Woods CG, Waxman SG (2010) A new Nav1.7 sodium channel mutation I234T in a child with severe pain. Eur J Pain 14:944-950
65. Reimann F, Cox JJ, Belfer I, Diatchenko L, Zaykin DV, McHale DP, Drenth JP, Dai F, Wheeler J, Sanders F, Wood L, Wu TX, Karppinen J, Nikolajsen L, Mannikko M, Max MB, Kiselycznyk C, Poddar M, Te Morsche RH, Smith S, Gibson D, Kelempisioti A, Maixner W, Gribble FM, Woods CG (2010) Pain perception is altered by a nucleotide polymorphism in SCN9A. Proc Natl Acad Sci USA. doi:10.1073/pnas.0913181107
66. Estacion M, Harty TP, Choi J-S, Tyrrell L, Dib-Hajj SD, Waxman SG (2009) A sodium channel gene SCN9A polymorphism that increases nociceptor excitability. Ann Neurol 66:862-866
67. Samuels ME, te Morsche RHM, Lynch ME, Drenth JPH (2008) Compound heterozygosity in sodium channel Nav1.7 in a family with hereditary erythermalgia. Mol Pain 4:21
68. Kremeyer B, Lopera F, Cox JJ, Momin A, Rugiero F, Marsh S, Woods CG, Jones NG, Paterson KJ, Fricker FR, Villegas A, Acosta N, Pineda-Trujillo NG, Ramirez JD, Zea J, Burley MW, Bedoya G, Bennett DL, Wood JN, Ruiz-Linares A (2010) A gain-of-function mutation in TRPA1 causes familial episodic pain syndrome. Neuron 66(5):671-680
69. Montell C (2005) Drosophila TRP channels. Pflügers Arch Eur J Physiol 451:19-28
70. Story GM, Peier AM, Reeve AJ, Eid SR, Mosbacher J, Hricik TR, Earley TJ, Hergarden AC, Andersson DA, Hwang SW, McIntyre P, Jegla T, Bevan S, Patapoutian A (2003) ANKTM1, a TRP-like channel expressed in nociceptive neurons, is activated by cold temperatures. Cell 112(6):819-829 (Pubitemid 36378884)
71. Jordt S-E, Bautista DM, Chuang H-H, McKemy DD, Zygmunt PM, Högestätt ED, Meng ID, Julius D (2004) Mustard oils and cannabinoids excite sensory nerve fibres through the TRP channel ANKTM1. Nature 427:260-265 (Pubitemid 38112043)
72. McKemy DD (2005) How cold is it? TRPM8 and TRPA1 in the molecular logic of cold sensation. Mol Pain 1(1):16
73. Peier AM, Moqrich A, Hergarden AC, Reeve AJ, Andersson DA, Story GM, Earley TJ, Dragoni I, McIntyre P, Bevan S, Patapoutian A (2002) ATRP channel that senses cold stimuli and menthol. Cell 108(5):705-715 (Pubitemid 34241429)
74. Eid SR, Cortright DN (2009) Transient receptor potential channels on sensory nerves. Handbook of experimental pharmacology. Springer, Berlin, pp 261-281
75. Poulsen L, Brosen K, Arendt-Nielsen L, Gram LF, Elbaek K, Sindrup SH (1996) Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects. Eur J Clin Pharmacol 51(3-4):289-295 (Pubitemid 26422976)
76. Collart L, Luthy C, Favario-Constantin C, Dayer P (1993) Duality of the analgesic effect of tramadol in humans. Schweiz Med Wochenschr 123(47):2241-2243 (Pubitemid 23353395)
77. Madadi P, Koren G, Cairns J, Chitayat D, Gaedigk A, Leeder JS, Teitelbaum R, Karaskov T, Aleksa K (2007) Safety of codeine during breastfeeding: fatal morphine poisoning in the breastfed neonate of a mother prescribed codeine. Can Fam Physician 53(1):33-35 (Pubitemid 46166581)
78. Koren G, Cairns J, Chitayat D, Gaedigk A, Leeder SJ (2006) Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet 368(9536):704 (Pubitemid 44223697)
79. Ferreirós N, Dresen S, Hermanns-Clausen M, Auwaerter V, Thierauf A, Müller C, Hentschel R, Trittler R, Skopp G, Weinmann W (2009) Fatal and severe codeine intoxication in 3-year-old twins-interpretation of drug and metabolite concentrations. Int J Leg Med 123:387-394
80. Voronov P, Przybylo HJ, Jagannathan N (2007) Apnea in a child after oral codeine: a genetic variant - an ultra-rapid metabolizer. Paediatr Anaesth 17(7):684-687 (Pubitemid 46911069)
81. Lötsch J, Rohrbacher M, Schmidt H, Doehring A, Brockmöller J, Geisslinger G (2009) Can extremely low or high morphine formation from codeine be predicted prior to therapy initiation? Pain 144(1-2):119-124
82. Dalen P, Frengell C, Dahl ML, Sjoqvist F (1997) Quick onset of severe abdominal pain after codeine in an ultrarapid metabolizer of debrisoquine. Ther Drug Monit 19(5):543-544 (Pubitemid 28116833)
83. Gasche Y, Daali Y, Fathi M, Chiappe A, Cottini S, Dayer P, Desmeules J (2004) Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med 351(27):2827-2831 (Pubitemid 40051906)
84. Campa D, Gioia A, Tomei A, Poli P, Barale R (2008) Association of ABCB1/MDR1 and OPRM1 gene polymorphisms with morphine pain relief. Clin Pharmacol Ther 83 (4):559-566 (Pubitemid 351417058)
85. Skarke C, Jarrar M, Schmidt H, Kauert G, Langer M, Geisslinger G, Lötsch J (2003) Effects of ABCB1 (multidrug resistance transporter) gene mutations on disposition and central nervous effects of loperamide in healthy volunteers. Pharmacogenetics 13(11):651-660 (Pubitemid 38316509)
86. Coller JK, Barratt DT, Dahlen K, Loennechen MH, Somogyi AA (2006) ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals. Clin Pharmacol Ther 80(6):682-690 (Pubitemid 44920224)
87. Park HJ, Shinn HK, Ryu SH, Lee HS, Park CS, Kang JH (2007) Genetic polymorphisms in the ABCB1 gene and the effects of fentanyl in Koreans. Clin Pharmacol Ther 81(4):539-546 (Pubitemid 46452300)
88. Szeto CY, Tang NL, Lee DT, Stadlin A (2001) Association between mu opioid receptor gene polymorphisms and Chinese heroin addicts. Neuroreport 12(6):1103-1106 (Pubitemid 32374725)
89. Shi J, Hui L, Xu Y, Wang F, Huang W, Hu G (2002) Sequence variations in the mu-opioid receptor gene (OPRM1) associated with human addiction to heroin. Hum Mutat 19(4):459-460
90. Tan EC, Tan CH, Karupathivan U, Yap EP (2003) Mu opioid receptor gene polymorphisms and heroin dependence in Asian populations. Neuroreport 14(4):569-572 (Pubitemid 36528992)
91. Hoehe MR, Kopke K, Wendel B, Rohde K, Flachmeier C, Kidd KK, Berrettini WH, Church GM (2000) Sequence variability and candidate gene analysis in complex disease: association of mu opioid receptor gene variation with substance dependence. Hum Mol Genet 9(19):2895-2908
92. Crowley JJ, Oslin DW, Patkar AA, Gottheil E, DeMaria PA Jr, O'Brien CP, Berrettini WH, Grice DE (2003) A genetic association study of the mu opioid receptor and severe opioid dependence. Psychiatr Genet 13(3):169-173 (Pubitemid 37082977)
93. Berrettini WH, Hoehe MR, Ferraro TN, Demaria PA, Gottheil E (1997) Human mu opioid receptor gene polymorphisms and vulnerability to substance abuse. Addict Biol 2(3):303-308 (Pubitemid 27326579)
94. Luo X, Kranzler HR, Zhao H, Gelernter J (2003) Haplotypes at the OPRM1 locus are associated with susceptibility to substance dependence in European-Americans. Am J Med Genet 120B(1):97-108 (Pubitemid 37059385)
95. Doehring A, Hentig N, Graff J, Salamat S, Schmidt M, Geisslinger G, Harder S, Lötsch J (2009) Genetic variants altering dopamine D2 receptor expression or function modulate the risk of opiate addiction and the dosage requirements of methadone substitution. Pharmacogenet Genomics 19(6):407-414
96. Barratt DT, Coller JK, Somogyi AA (2006) Association between the DRD2 A1 allele and response to methadone and buprenorphine maintenance treatments. Am J Med Genet B Neuropsychiatr Genet 141(4):323-331 (Pubitemid 43872882)
97. Proudnikov D, LaForge KS, Hofflich H, Levenstien M, Gordon D, Barral S, Ott J, Kreek MJ (2006) Association analysis of polymorphisms in serotonin 1B receptor (HTR1B) gene with heroin addiction: a comparison of molecular and statistically estimated haplotypes. Pharmacogenet Genomics 16(1):25-36 (Pubitemid 41803874)
98. Proudnikov D, Hamon S, Ott J, Kreek MJ (2008) Association of polymorphisms in the melanocortin receptor type 2 (MC2R, ACTH receptor) gene with heroin addiction. Neurosci Lett 435(3):234-239
99. Goldman D, Oroszi G, Ducci F (2005) The genetics of addictions: uncovering the genes. Nat Rev Genet 6(7):521-532 (Pubitemid 40910429)
100. Mogil JS (2009) Are we getting anywhere in human pain genetics? Pain 146(3):231-232
101. Lötsch J, von Hentig N, Freynhagen R, Griessinger N, Zimmermann M, Doehring A, Rohrbacher M, Sittl R, Geisslinger G (2009) Cross-sectional analysis of the influence of currently known pharmacogenetic modulators on opioid therapy in outpatient pain centers. Pharmacogenet Genomics 19(6):429-436
102. Lötsch J, Geisslinger G (2007) Current evidence for a modulation of nociception by human genetic polymorphisms. Pain 132(1-2):18-22 (Pubitemid 47494570)
103. Lötsch J, Geisslinger G (2010) Pharmacogenetics of new analgesics. Br J Pharmacol. doi:10.1111/j.1476-5381.2010.01074.x
104. Nicholson GA, Dawkins JL, Blair IP, Kennerson ML, Gordon MJ, Cherryson AK, Nash J, Bananis T (1996) The gene for hereditary sensory neuropathy type I (HSN-I) maps to chromosome 9q22.1-q22.3. Nat Genet 13(1):101-104 (Pubitemid 126528237)
105. Bejaoui K, Wu C, Scheffler MD, Haan G, Ashby P, Wu L, de Jong P, Brown RH Jr (2001) SPTLC1 is mutated in hereditary sensory neuropathy, type 1. Nat Genet 27(3):261-262 (Pubitemid 32201845)
106. Dawkins JL, Hulme DJ, Brahmbhatt SB, Auer-Grumbach M, Nicholson GA (2001) Mutations in SPTLC1, encoding serine palmitoyltransferase, long chain base subunit-1, cause hereditary sensory neuropathy type I. Nat Genet 27(3):309-312 (Pubitemid 32201853)
107. Lafreniere RG, MacDonald ML, Dube MP, MacFarlane J, O'Driscoll M, Brais B, Meilleur S, Brinkman RR, Dadivas O, Pape T, Platon C, Radomski C, Risler J, Thompson J, Guerra-Escobio AM, Davar G, Breakefield XO, Pimstone SN, Green R, Pryse-Phillips W, Goldberg YP, Younghusband HB, Hayden MR, Sherrington R, Rouleau GA, Samuels ME (2004) Identification of a novel gene (HSN2) causing hereditary sensory and autonomic neuropathy type II through the Study of Canadian Genetic Isolates. Am J Hum Genet 74(5):1064-1073 (Pubitemid 38568977)
108. Riviere JB, Verlaan DJ, Shekarabi M, Lafreniere RG, Benard M, Der Kaloustian VM, Shbaklo Z, Rouleau GA (2004) A mutation in the HSN2 gene causes sensory neuropathy type II in a Lebanese family. Ann Neurol 56(4):572-575 (Pubitemid 39319350)
109. Blumenfeld A, Slaugenhaupt SA, Axelrod FB, Lucente DE, Maayan C, Liebert CB, Ozelius LJ, Trofatter JA, Haines JL, Breakefield XO et al (1993) Localization of the gene for familial dysautonomia on chromosome 9 and definition of DNA markers for genetic diagnosis. Nat Genet 4(2):160-164 (Pubitemid 23179100)
110. Slaugenhaupt SA, Blumenfeld A, Gill SP, Leyne M, Mull J, Cuajungco MP, Liebert CB, Chadwick B, Idelson M, Reznik L, Robbins C, Makalowska I, Brownstein M, Krappmann D, Scheidereit C, Maayan C, Axelrod FB, Gusella JF (2001) Tissue-specific expression of a splicing mutation in the IKBKAP gene causes familial dysautonomia. Am J Hum Genet 68(3):598-605 (Pubitemid 32202755)
111. Houlden H, King RH, Hashemi-Nejad A, Wood NW, Mathias CJ, Reilly M, Thomas PK (2001) A novel TRK A (NTRK1) mutation associated with hereditary sensory and autonomic neuropathy type V. Ann Neurol 49(4):521-525 (Pubitemid 32281337)
112. Goldberg YP, MacFarlane J, MacDonald ML, Thompson J, Dube MP, Mattice M, Fraser R, Young C, Hossain S, Pape T, Payne B, Radomski C, Donaldson G, Ives E, Cox J, Younghusband HB, Green R, Duff A, Boltshauser E, Grinspan GA, Dimon JH, Sibley BG, Andria G, Toscano E, Kerdraon J, Bowsher D, Pimstone SN, Samuels ME, Sherrington R, Hayden MR (2007) Loss-of- function mutations in the Nav1.7 gene underlie congenital indifference to pain in multiple human populations. Clin Genet 71(4):311-319 (Pubitemid 46690905)
113. Miura Y, Hiura M, Torigoe K, Numata O, Kuwahara A, Matsunaga M, Hasegawa S, Boku N, Ino H, Mardy S, Endo F, Matsuda I, Indo Y (2000) Complete paternal uniparental isodisomy for chromosome 1 revealed by mutation analyses of the TRKA (NTRK1) gene encoding a receptor tyrosine kinase for nerve growth factor in a patient with congenital insensitivity to pain with anhidrosis. Hum Genet 107(3):205-209
114. Klepstad P, Rakvag TT, Kaasa S, Holthe M, Dale O, Borchgrevink PC, Baar C, Vikan T, Krokan HE, Skorpen F (2004) The 118A>G polymorphism in the human mu-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease. Acta Anaesthesiol Scand 48(10):1232-1239 (Pubitemid 39490855)